Oliver Lagore Vanvalin Investment Group’s Prologis PLD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
$111K Buy
+990
New +$104K 0.04% 178
2024
Q4
$105K Hold
990
– – 0.03% 174
2024
Q3
$125K Hold
990
– – 0.03% 158
2024
Q2
$111K Hold
990
– – 0.03% 161
2024
Q1
$129K Hold
990
– – 0.04% 159
2023
Q4
$132K Sell
990
-35
-3% -$3.97K 0.05% 133
2023
Q3
$115K Hold
1,025
– – 0.05% 156
2023
Q2
$126K Sell
1,025
-33
-3% -$4.06K 0.05% 155
2023
Q1
$132K Buy
1,058
+990
+1,456% +$122K 0.06% 111
2022
Q4
$7.67K Sell
68
-4
-6% -$443 ﹤0.01% 399
2022
Q3
$7K Buy
72
+33
+85% +$4.09K ﹤0.01% 396
2022
Q2
$5K Buy
39
+4
+11% +$553 ﹤0.01% 418
2022
Q1
$6K Buy
+35
New +$5.34K ﹤0.01% 395

Other funds holding PLD

Oliver Lagore Vanvalin Investment Group's PLD Position: Q2 2025 in Review

Oliver Lagore Vanvalin Investment Group opened a new position in Prologis (PLD) in Q2 2025: 990 shares worth $111K. The stake represents 0.04% of the portfolio and ranks #178 among its holdings. This is a return to the name: Oliver Lagore Vanvalin Investment Group previously reported a position in PLD as recently as Q4 2024.

Oliver Lagore Vanvalin Investment Group first reported a position in PLD in Q1 2022 and has held it in 13 quarters since. The position peaked at $132K in Q1 2023. 1,493 funds tracked by Wall St. Rank hold PLD as of Q2 2025.

  • Oliver Lagore Vanvalin Investment Group held 990 shares of Prologis worth $111K as of Q2 2025.
  • Prologis was a new Oliver Lagore Vanvalin Investment Group position in Q2 2025.
  • Prologis made up 0.04% of Oliver Lagore Vanvalin Investment Group's portfolio in Q2 2025, its #178 holding.
  • Oliver Lagore Vanvalin Investment Group first reported a position in Prologis in Q1 2022 and has held it in 13 quarters since.
  • Oliver Lagore Vanvalin Investment Group's Prologis position peaked at $132K in Q1 2023.
  • 1,493 funds tracked by Wall St. Rank held Prologis as of Q2 2025.

Based on Oliver Lagore Vanvalin Investment Group's 13F filing for Q2 2025, filed 10 Jul 2025.